Yeo D - Search Results

1

Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging.

Yeo D, Kao S, Gupta R, Wahlroos S, Bastian A, Strauss H, Klemm V, Shrestha P, Ramirez AB, Costandy L, Huston R, Gardner BS, Grimison P, Clark JR, Rasko JEJ. Yeo D, et al. Front Oncol. 2023 Mar 27;13:1141228. doi: 10.3389/fonc.2023.1141228. eCollection 2023. Front Oncol. 2023. PMID: 37051527 Free PMC article.

2

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma.

Castelletti L, Yeo D, van Zandwijk N, Rasko JEJ. Castelletti L, et al. Among authors: yeo d. Biomark Res. 2021 Feb 15;9(1):11. doi: 10.1186/s40364-021-00264-1. Biomark Res. 2021. PMID: 33588928 Free PMC article. Review.

3

Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma.

Yeo D, Castelletti L, van Zandwijk N, Rasko JEJ. Yeo D, et al. Cancers (Basel). 2021 Aug 4;13(16):3932. doi: 10.3390/cancers13163932. Cancers (Basel). 2021. PMID: 34439085 Free PMC article. Review.

4

Mapping oncogenic protein interactions for precision medicine.

Sharifi Tabar M, Francis H, Yeo D, Bailey CG, Rasko JEJ. Sharifi Tabar M, et al. Among authors: yeo d. Int J Cancer. 2022 Jul 1;151(1):7-19. doi: 10.1002/ijc.33954. Epub 2022 Feb 14. Int J Cancer. 2022. PMID: 35113472 Free PMC article. Review.

5

Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells.

Yeo D, Bastian A, Strauss H, Saxena P, Grimison P, Rasko JEJ. Yeo D, et al. Int J Mol Sci. 2022 Jan 31;23(3):1671. doi: 10.3390/ijms23031671. Int J Mol Sci. 2022. PMID: 35163592 Free PMC article. Review.

6

The next wave of cellular immunotherapies in pancreatic cancer.

Yeo D, Giardina C, Saxena P, Rasko JEJ. Yeo D, et al. Mol Ther Oncolytics. 2022 Feb 1;24:561-576. doi: 10.1016/j.omto.2022.01.010. eCollection 2022 Mar 17. Mol Ther Oncolytics. 2022. PMID: 35229033 Free PMC article. Review.

7

Locoregional delivery of CAR-T cells in the clinic.

Sagnella SM, White AL, Yeo D, Saxena P, van Zandwijk N, Rasko JEJ. Sagnella SM, et al. Among authors: yeo d. Pharmacol Res. 2022 Aug;182:106329. doi: 10.1016/j.phrs.2022.106329. Epub 2022 Jun 27. Pharmacol Res. 2022. PMID: 35772645 Review.

8

High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma.

Chu GJ, Linton A, Kao S, Klebe S, Adelstein S, Yeo D, Rasko JEJ, Cooper WA. Chu GJ, et al. Among authors: yeo d. Histopathology. 2023 Aug;83(2):202-210. doi: 10.1111/his.14916. Epub 2023 Apr 11. Histopathology. 2023. PMID: 37040900 Free PMC article.

9

Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity.

Chu GJ, Bailey CG, Nagarajah R, Liang O, Metierre C, Sagnella SM, Castelletti L, Yeo D, Adelstein S, Rasko JEJ. Chu GJ, et al. Among authors: yeo d. Cytotherapy. 2024 Apr;26(4):325-333. doi: 10.1016/j.jcyt.2024.01.011. Epub 2024 Feb 13. Cytotherapy. 2024. PMID: 38349311

10

Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer.

Yeo D, Phillips P, Baldwin GS, He H, Nikfarjam M. Yeo D, et al. Int J Cancer. 2017 May 1;140(9):2101-2111. doi: 10.1002/ijc.30615. Epub 2017 Feb 7. Int J Cancer. 2017. PMID: 28109008 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

420 results

Search Page